Type 3 Procollagen Peptide in Bronchoalveolar Lavage Fluid: Pulmonary Function

21 Nov
2014

Type 3 Procollagen Peptide in Bronchoalveolar Lavage Fluid: Pulmonary FunctionPulmonary Function
No correlation was noted between type 3 procollagen peptide levels and indices of pulmonary (unction. Patients with abnormal % FVC or % Dsb levels (<80 percent of predicted normal) had similar type 3 procollagen peptide levels to those with normal % FVC or % Dsb levels. As indicated above, erythema nodosum and uveitis are generally associated with a good prognosis in sarcoidosis; thus, functional data were reanalyzed excluding patients presenting with these symptoms. However, even when these patients were excluded, no association between percent FVC or percent Dsb and lavage type 3 procollagen peptide levels was observed. Similarly, pulmonary function in the 25 percent of patients with highest procollagen peptide levels (excluding patients with erythema nodosum or uveitis) did not differ from pulmonary function in the 25 percent of patients with lowest type 3 procollagen peptide levels. so

Follow-up
During the 12-month follow-up period, 28 patients were placed on corticosteroid therapy to alleviate functional deterioration. Therapy decisions were taken on clinical grounds without reference to lavage type III procollagen peptide levels. A further 12 patients, who remained untreated, displayed a decrease in pulmonary function, as indicated by a drop of 10 percent or more in the predicted normal values of either FVC or Dsb. Lavage type 3 procollagen peptide levels in patients showing deterioration (median, 0.86; range, 0 to 20.2 ng/mg protein) were similar to those of patients who displayed no evidence of functional deterioration on follow-up (median, 1.17; range, 0 to 15.8 ng/mg protein). No association was observed between lavage type 3 procollagen peptide levels and change in percent FVC or percent Dsb during the follow-up period. Similarly, no difference was noted between the 25 percent of patients with highest procollagen peptide levels and the 25 percent with lowest levels in respect of deterioration on follow-up. Eight of the 21 patients with highest lavage type 3 procollagen peptide levels were treated on follow-up and a further three displayed a decrease in pulmonary function at the last follow-up visit. This pattern was no different from that observed in the 21 patients with lowest lavage type 3 procollagen peptide levels, five of whom were treated and three of whom displayed a decrease in pulmonary function on follow-up.

top